Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
GLAUKOS Corporation operates a patent portfolio in the Medical Devices & Mechanical Engineering technology area. The company currently has 7 pending office actions. These actions are distributed among 7 distinct examiners and 4 distinct art units. This high level of dispersion means that every pending matter is being handled by a different examiner. LEVY, BRANDON WILLIAM is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Given that there are 7 pending office actions and 7 distinct examiners, each examiner is responsible for 1 action. The fact that there are 4 distinct art units indicates a range of medical device and mechanical engineering research being patented. This diversity requires a flexible prosecution strategy, as the company must interact with 7 different examiners across 4 different administrative groups, each with its own examination culture and technical focus for the 7 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (57%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEVY, BRANDON WILLIAM | 1 | 62.7% | +46.3% |
| FARRAR, LAUREN PENG | 1 | 78.6% | +15.5% |
| TURKOWSKI, KAYLA MARIE | 1 | 65.8% | +49.2% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| DARB, HAMZA A. | 1 | 74.4% | +30.9% |
| TOTH, KAREN E | 1 | 46.4% | +25.8% |
| MANNAN, MIKAIL A | 1 | 68.5% | +23.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18310109 | DRUG-ELUTING OCULAR IMPLANT | DARB, HAMZA A. | 36d |
| 18913142 | INSERTION SYSTEM FOR DELIVERY OF ACTIVE PHARMACEUTICAL AGENTS INSIDE THE EYE | LEVY, BRANDON WILLIAM | — |
| 18641263 | IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME | FARRAR, LAUREN PENG | — |
| 18407936 | DRUG DELIVERY IMPLANTS WITH BI-DIRECTIONAL DELIVERY CAPACITY AND METHODS OF USING SAME | TURKOWSKI, KAYLA MARIE | — |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | BASQUILL, SEAN M | — |
| 17844497 | INTRAOCULAR PHYSIOLOGICAL SENSOR | TOTH, KAREN E | — |
| 17125466 | OCULAR TISSUE PERFORATION DEVICE | MANNAN, MIKAIL A | — |
| Art Unit | Apps |
|---|---|
| 3783 | 2 |
| 1614 | 1 |
| 3791 | 1 |
| 3774 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18913142 | INSERTION SYSTEM FOR DELIVERY OF ACTIVE PHARMACEUTICAL AGENTS INSIDE THE EYE | LEVY, BRANDON WILLIAM | — | §103 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18641263 | IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME | FARRAR, LAUREN PENG | — | §102§103DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18407936 | DRUG DELIVERY IMPLANTS WITH BI-DIRECTIONAL DELIVERY CAPACITY AND METHODS OF USING SAME | TURKOWSKI, KAYLA MARIE | 3783 | §103§112DP | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Jul 26, 2023 |
| 18310109 | DRUG-ELUTING OCULAR IMPLANT | DARB, HAMZA A. | 3783 | §103 | Non-Final OA | 36d | Pending | May 01, 2023 |
| 17844497 | INTRAOCULAR PHYSIOLOGICAL SENSOR | TOTH, KAREN E | 3791 | §112 | Final Rejection | — | Pending | Jun 20, 2022 |
| 17125466 | OCULAR TISSUE PERFORATION DEVICE | MANNAN, MIKAIL A | 3774 | §103 | Final Rejection | — | Pending | Dec 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial